Search

Your search keyword '"metastatic gastric cancer"' showing total 7 results
Start Over Descriptor "metastatic gastric cancer" Publisher future medicine ltd
7 results on '"metastatic gastric cancer"'

1. Treatment strategies for metastatic gastric cancer: chemotherapy, palliative surgery or radiotherapy?

Author

Liang, Xiao, Zhu, Jiamin, Li, Yuanye, Xu, Yiren, Chen, Kai, Lv, Liting, and Mao, Weidong

Subjects
STOMACH tumors, REPORTING of diseases, PROGNOSIS, METASTASIS, TREATMENT effectiveness, TUMOR classification, GASTRECTOMY, KAPLAN-Meier estimator, ONCOLOGIC surgery, PROPORTIONAL hazards models, PALLIATIVE treatment
Abstract

Aim: This study explored whether chemotherapy combined with palliative surgery and/or radiotherapy is a possible treatment for metastatic gastric cancer. Materials & methods: Patients were divided into groups according to treatments. COX models were used to explore prognostic factors. Kaplan-Meier models and log-rank tests were used to analyze outcomes. Outcomes were analyzed before and after propensity score matching. Results: Chemotherapy combined with gastrectomy or metastasectomy prolongs the survival time compared with chemotherapy alone (p < 0.05). Chemotherapy combined with gastrectomy plus metastasectomy and/or radiation therapy also prolongs the survival time (p < 0.05). Conclusion: Chemotherapy combined with gastrectomy could be a more effective treatment for metastatic gastric cancer. Chemotherapy combined with gastrectomy plus metastasectomy and/or radiation therapy could also be a promising treatment. [ABSTRACT FROM AUTHOR]

Published
2020
Full Text
View/download PDF

2. Systemic-inflammation-based score can predict prognosis in metastatic gastric cancer patients before first-line chemotherapy.

Author

Petrillo, Angelica, Laterza, Maria Maddalena, Tirino, Giuseppe, Pompella, Luca, Ventriglia, Jole, Pappalardo, Annalisa, Famiglietti, Vincenzo, Martinelli, Erika, Ciardiello, Fortunato, Orditura, Michele, Galizia, Gennaro, and De Vita, Ferdinando

Abstract

Aim: Systemic inflammatory response affects survival of gastric cancer (GC) patients. This study was carried out to create a prognostic inflammatory-based score to predict survival in metastatic GC (mGC) before first-line chemotherapy. Materials & methods: We studied the prognostic value of neutrophil–lymphocyte ratio (NLR) and platelet–lymphocyte ratio in 151 patients with mGC at the diagnosis. Results: Median overall survival (OS) was significantly lower in patients with high NLR. Performance status 1–2 according to the Eastern Cooperative Oncology Group scale and NLR were predictors of shorter OS at multivariate analysis. Based on these results, we defined a prognostic OS score, showing a better median OS in favorable risk group. Conclusion: Elevated pretreatment NLR and Eastern Cooperative Oncology Group are independent predictors of shorter OS in mGC patients before first-line chemotherapy. [ABSTRACT FROM AUTHOR]

Published
2018
Full Text
View/download PDF

3. Role of nutritional care and general guidance for patients with advanced or metastatic gastric cancer

Author

Yongzhe Piao and Takuro Mizukami

Subjects
Cancer Research, medicine.medical_specialty, medicine.medical_treatment, Metastatic gastric cancer, Cachexia, 03 medical and health sciences, 0302 clinical medicine, Quality of life (healthcare), Stomach Neoplasms, medicine, Humans, 030212 general & internal medicine, Nutritional care, Intensive care medicine, Chemotherapy, Nutritional Support, business.industry, Malnutrition, Cancer, Nutritional status, General Medicine, medicine.disease, Nutrition Assessment, Oncology, 030220 oncology & carcinogenesis, Quality of Life, business
Abstract

Patients with advanced or metastatic gastric cancer often suffer from malnutrition, which can have an impact on quality of life, increase the toxicity of chemotherapy and reduce overall survival. Options available to the clinician to manage a patient's nutritional status include screening and assessment of malnutrition at diagnosis, monitoring during the 'cancer journey', early detection of precachexia and the ongoing use of a multidisciplinary team (oncologists, other medical specialists and nutritionists). Because malnutrition is frequently overlooked and under treated in patients with advanced or metastatic gastric cancer, this narrative review focuses on the clinical meaning of nutritional status in gastric cancer and provides general guidance regarding nutritional care management for patients with advanced or metastatic gastric cancer.Lay abstract Patients with gastric cancer that has spread to other parts of the body often suffer from malnutrition. This can impact patients’ lives, increase side effects from cancer treatment and reduce life expectancy. This article provides guidance for healthcare providers on nutritional care for patients with gastric cancer. Key ways healthcare providers can contribute to nutritional care include: looking for malnutrition when a patient is diagnosed with gastric cancer; watching carefully for malnutrition during cancer treatment; keeping a lookout for early signs of extreme weight loss and muscle wasting; and involving a team of healthcare providers with a broad range of expertise in patients’ nutritional care.

Published
2021

4. Healthcare utilization and total costs of care among patients with advanced metastatic gastric and esophageal cancer

Author

Pranav Abraham, J. Gricar, Hiangkiat Tan, Liya Wang, Ronan J. Kelly, and Zhengzheng Jiang

Subjects
Adult, Male, Cancer Research, medicine.medical_specialty, Adolescent, Esophageal Neoplasms, Newly diagnosed, Metastatic gastric cancer, Young Adult, 03 medical and health sciences, 0302 clinical medicine, Stomach Neoplasms, Internal medicine, Antineoplastic Combined Chemotherapy Protocols, Humans, Medicine, In patient, Aged, Retrospective Studies, Cisplatin, business.industry, 030503 health policy & services, Health Care Costs, General Medicine, Middle Aged, Patient Acceptance of Health Care, Esophageal cancer, medicine.disease, United States, Oncology, Healthcare utilization, 030220 oncology & carcinogenesis, Female, Per patient per month, 0305 other medical science, business, Epirubicin, medicine.drug
Abstract

Aim: Study first-line (1L) treatment patterns and economic outcomes among patients with advanced metastatic gastric cancer (GC) and esophageal cancer (EC). Materials & methods: Newly diagnosed patients with systemic GC and EC treatments were identified between 1 January 2011 and 31 July 2017; costs were presented as per patient per month (PPPM) basis. Results: Study included 392 GC and 436 EC patients. Most frequently used 1L regimens were: 5-fluorouracil (5-FU) + oxaliplatin (22.5%) and epirubicin + cisplatin + 5-FU (ECF)/ECF modifications (21.9%) in patients with GC; and carboplatin + paclitaxel (29.6%) and 5-FU + oxaliplatin (11.5%) in EC patients. Mean all-cause costs were US$16,242 PPPM for GC, and $18,384 PPPM for EC during 1L treatment. Conclusion: GC and EC were resource intensive and costly. High costs and short treatment durations underscored a gap in care in 1L treatment.

Published
2021

5. Selecting patients for gastrectomy in metastatic esophago-gastric cancer: clinics and pathology are not enough.

Author

Fornaro, Lorenzo, Fanotto, Valentina, Musettini, Gianna, Uccello, Mario, Rimassa, Lorenza, Vivaldi, Caterina, Fontanella, Caterina, Leone, Francesco, Giampieri, Riccardo, Rosati, Gerardo, Lencioni, Monica, Santini, Daniele, Donato, Samantha Di, Tomasello, Gianluca, Brunetti, Oronzo, Pietrantonio, Filippo, Bergamo, Francesca, Scartozzi, Mario, Avallone, Antonio, and Lutrino, Stefania Eufemia

Subjects
COMBINED modality therapy, COMPARATIVE studies, ESOPHAGUS, ESOPHAGEAL tumors, GASTRECTOMY, RESEARCH methodology, MEDICAL cooperation, METASTASIS, RESEARCH, STOMACH tumors, TUMOR classification, EVALUATION research, TREATMENT effectiveness, RETROSPECTIVE studies, PATIENT selection
Abstract

Aim: To evaluate the impact on overall survival (OS) of gastrectomy in asymptomatic metastatic esophago-gastric cancer.Patients& Methods: Five hundred and thirteen patients were included. The role of surgery and other clinico-pathological factors was evaluated by univariate and Cox regression analyses. OS was the primary end point.Results: Multivariate analysis confirmed that gastrectomy was a predictor of longer OS (p < 0.001), as well as preserved performance status and benefit from first-line chemotherapy. None of the investigated clinico-pathological variables identified preferable candidates for surgery (all p > 0.05).Conclusion: Palliative gastrectomy might play a role in asymptomatic metastatic esophago-gastric cancer patients with good performance status who received benefit from first-line chemotherapy. Future prospective trials integrating tumor biology among inclusion criteria may help defining the optimal candidates. [ABSTRACT FROM AUTHOR]

Published
2017
Full Text
View/download PDF

6. Current advances in targeted therapies for metastatic gastric cancer: improving patient care

Author

Yelena Y. Janjigian, Ramon Andrade de Mello, Hakaru Tadokoro, Pedro Castelo-Branco, Ines-de-Paula Monteiro, Pedro Nazareth Aguiar, Raelson Rodrigues Miranda, Thiago Pimentel Muniz, and Nora Manoukian Forones

Subjects
0301 basic medicine, Oncology, Cancer Research, medicine.medical_specialty, Receptor, ErbB-2, medicine.medical_treatment, Angiogenesis Inhibitors, Antineoplastic Agents, Patient care, Targeted therapy, Metastatic gastric cancer, Double blind, 03 medical and health sciences, 0302 clinical medicine, Stomach Neoplasms, Internal medicine, Drug Discovery, medicine, Humans, Gastric tumor, Molecular Targeted Therapy, Neoplasm Metastasis, Protein Kinase Inhibitors, Predictive biomarker, Clinical Trials as Topic, business.industry, General Medicine, Advanced gastric cancer, Quality Improvement, ErbB Receptors, Treatment Outcome, 030104 developmental biology, 030220 oncology & carcinogenesis, Patient Care, Open label, business
Abstract

In this article, we review the literature on the current advances in targeted therapies for metastatic gastric cancer aimed at improving patient care. We conclude that the key to guiding targeted therapy is individual biomarkers, which are not completely elucidated. HER2 overexpression is the only predictive biomarker currently in use. Furthermore, it is necessary to understand that gastric tumors are heterogeneous; therefore, is impossible to evaluate a novel biological compound without evaluating personal biomarkers. The selection of patients who are able to receive each treatment is paramount for improving advanced gastric cancer survival and reducing unnecessary costs.

Published
2016

7. Serum HER2 extracellular domain as a potential alternative for tissue HER2 status in metastatic gastric cancer patients

Author

Lin Shen, Yanyan Li, Qingqing Li, Yi Liu, Zhi Peng, Xiaotian Zhang, Jun Zhou, and Ming Lu

Subjects
Adult, Male, Pathology, medicine.medical_specialty, genetic structures, Receptor, ErbB-2, Chemiluminescence immunoassay, Clinical Biochemistry, Gastroenterology, Metastatic gastric cancer, Young Adult, Stomach Neoplasms, Internal medicine, Drug Discovery, Biomarkers, Tumor, medicine, Extracellular, Humans, Neoplasm Metastasis, skin and connective tissue diseases, neoplasms, Aged, Retrospective Studies, Receiver operating characteristic, business.industry, Biochemistry (medical), Area under the curve, Middle Aged, Serum concentration, Protein Structure, Tertiary, Gene Expression Regulation, Neoplastic, Solubility, Female, Extracellular Space, business
Abstract

Aim: We investigated whether serum concentrations of the HER2 extracellular domain (ECD) can be used as an alternative to test tissue HER2 status in metastatic gastric cancer. Materials & methods: A total of 133 cases of metastatic gastric cancer were included in present study. Serum HER2 ECD was measured by chemiluminescence immunoassay (CLIA). Receiver operating characteristic curve analysis was used to determine optimal serum HER2 ECD concentrations for differentiation between positive and negative HER2 status. Results: The median level of serum HER2 ECD was 9.6 ng/ml in metastatic gastric cancer patients. There was a significant relationship between serum and tissue levels of HER2 protein (p < 0.001). Area under the curve for serum HER2 ECD was 0.771 (95% CI: 0.682–0.860). Conclusion: Levels of serum HER2 ECD are highly correlated with tissue HER2 status in metastatic gastric cancer. Serum HER2 ECD assay can be considered as a potential alternative for tissue HER2 status.

Published
2014

Catalog

Books, media, physical & digital resources
See catalog results